Back to top
more

Oncolytics Biotech (ONCY)

(Delayed Data from NSDQ)

$1.09 USD

1.09
219,161

+0.01 (0.93%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $1.08 -0.01 (-0.92%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ONCY

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Oncolytics Biotech Inc. [ONCY]

Reports for Purchase

Showing records 1 - 20 ( 143 total )

Company: Oncolytics Biotech Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

03/08/2024

Company Report

Pages: 8

4Q23 Results; Pelareorep Phase 3 Trials in Breast and Pancreatic Cancers to Start in 2024; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Oncolytics Biotech Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

02/14/2024

Daily Note

Pages: 3

GOBLET Expands to Evaluate Lead Program Pelareorep in Combination Setting For Advanced Anal Cancer

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 10.00

Research Provided by a Third Party

Company: Oncolytics Biotech Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

01/19/2024

Company Report

Pages: 6

Collaboration Discussions Gaining Momentum on Lead Program Pelareorep; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Oncolytics Biotech Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

01/04/2024

Daily Note

Pages: 3

Phase 3 Start in Pancreatic Cancer Expected in Mid-2024; Provides Guidance For 2024 in Line With Expectations; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 5.00

Research Provided by a Third Party

Company: Oncolytics Biotech Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

12/07/2023

Daily Note

Pages: 3

Pelareorep Awakens Expansion of Antitumor T Cells in Breast Cancer Trial; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 5.00

Research Provided by a Third Party

Company: Oncolytics Biotech Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

11/13/2023

Company Report

Pages: 8

Pivoting Clinical Development Strategy For Pelareorep in Pancreatic Cancer; Moderating Price Target to $5; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Oncolytics Biotech Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

11/09/2023

Daily Note

Pages: 3

GOBLET Meets Success Criteria For Efficacy in Anal Cancer

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 5.00

Research Provided by a Third Party

Company: Oncolytics Biotech Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

11/07/2023

Company Report

Pages: 8

3Q23 Results; Lead Oncolytic Agent Pelareorep Progressing in Multiple Pancreatic Cancer Trials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Oncolytics Biotech Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

10/24/2023

Company Report

Pages: 8

Signals of Durable Clinical Benefit With Pelareorep in Pancreatic Cancer Emerge From Phase 1/2 Update at ESMO; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Oncolytics Biotech Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

09/19/2023

Industry Report

Pages: 14

Key Takeaways From 25th Annual Global Conference: Multiple Underappreciated Programs to Shine in 2H23 and 2024

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Oncolytics Biotech Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

08/16/2023

Company Report

Pages: 7

2Q23 Results; Lead Oncolytic Agent Pelareorep Progressing in Pancreatic Cancer Pivotal Platform Trial; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Oncolytics Biotech Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

06/29/2023

Company Report

Pages: 7

Lead Program Pelareorep Expected to Advance to Phase 3 in Pancreatic Cancer Trial; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Oncolytics Biotech Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

06/07/2023

Company Report

Pages: 7

KOL Event Takeaways: Lead Candidate Pelareorep Expected to Advance to Registrational Program in Breast Cancer; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Oncolytics Biotech Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

05/26/2023

Company Report

Pages: 7

ASCO Update; Pelareorep Demonstrates Potential in Metastatic Breast Cancer; KOL Event Expected June 5; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Oncolytics Biotech Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

05/09/2023

Company Report

Pages: 8

1Q23 Results; Pipeline Progressing on Track; Phase 2 Breast Cancer, Preclinical CAR T Combination Data Expected at ASCO

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Oncolytics Biotech Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

03/14/2023

Company Report

Pages: 8

4Q22 Results; Lead Oncolytic Virus Program Pelareorep on Track for Several Data Updates in 1H23; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Oncolytics Biotech Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

11/23/2022

Company Report

Pages: 11

Lead Program Pelareorep Continues to Shine; KOL Event Highlights Compelling Pancreatic Cancer Data; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Oncolytics Biotech Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

08/18/2022

Company Report

Pages: 8

2Q22 Earnings; Lead Oncolytic Virus Program Pelareorep Progressing; Multiple Updates on Track for 2H22 and 1H23

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Oncolytics Biotech Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

07/15/2022

Company Report

Pages: 7

Lead Oncolytic Virus Program, Pelareorep, Generates Initial Efficacy Signal in Pancreatic Cancer

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Oncolytics Biotech Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

05/09/2022

Company Report

Pages: 8

1Q22 Results; Multiple Data Updates on Lead Oncolytic Virus Program Pelareorep Expected in 2H22

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party